Breakthrough venous thromboembolic events in five patients with COVID-19 on direct oral anticoagulants.
J Clin Pharm Ther
; 46(2): 519-523, 2021 Apr.
Article
in English
| MEDLINE | ID: covidwho-939769
ABSTRACT
WHAT IS KNOWN AND OBJECTIVE:
Coronavirus disease 2019 (COVID-19) is associated with increased risk of venous thromboembolism (VTE). Guidance for VTE prophylaxis continues to evolve, including addressing direct oral anticoagulants (DOACs) continued upon hospitalization. CASE SUMMARIES We present 5 patients hospitalized for COVID-19 while on DOACs. Four patients had atrial fibrillation and had a previous VTE. Four patients developed acute VTE and one developed stroke-like symptoms. Monitoring D-dimer assisted with the detection of VTE. Three patients died, and two were discharged alive. WHAT IS NEW ANDCONCLUSION:
Therapeutic failure with DOACs appears to be commonplace in COVID-19. Further research is needed to determine whether there is an underlying cause to this association.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Atrial Fibrillation
/
Fibrin Fibrinogen Degradation Products
/
Venous Thromboembolism
/
Factor Xa Inhibitors
/
COVID-19
/
COVID-19 Drug Treatment
Type of study:
Case report
/
Diagnostic study
/
Prognostic study
Topics:
Long Covid
/
Vaccines
Limits:
Aged
/
Female
/
Humans
/
Male
Language:
English
Journal:
J Clin Pharm Ther
Journal subject:
Pharmacy
/
Therapeutics
Year:
2021
Document Type:
Article
Affiliation country:
Jcpt.13311
Similar
MEDLINE
...
LILACS
LIS